25-gauge PPV: safe and effective

Article

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes.

25-gauge pars plana vitrectomy (PPV) appears to be safe and effective for the treatment of epiretinal membranes, according to a report published online ahead of print by Der Ophthalmologe.

Albrecht Lommatzsch and colleagues from St. Franziskus Hospital MÜnster, Germany investigated 625 eyes from 620 patients who were operated on using the 25-gauge technique between 2002 and 2006.

The epiretinal membranes were successfully removed in all patients and 329 eyes were analyzed with long-term follow-up over 3.1 years. The mean improvement in visual acuity (VA) before and after surgery was -09.41 in logMAR and normal intraocular pressure (IOP) was observed in all patients one week postoperatively. In nine patients with postoperative hypotony and choroidal detachment, an additional suture was required and seven patients developed a retinal detachment. No patients developed endophthalmitis during the follow-up period.

The 25-gauge PPV technique, according to the researchers, appears to be both safe and effective.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
Related Content
© 2025 MJH Life Sciences

All rights reserved.